Patheon To Merge With DSM Pharma Business To Create New Company
This article was originally published in The Pink Sheet Daily
Executive Summary
The newly created company hopes to be a full-service outlet for its pharmaceutical clients now that its offerings will be in more territories and encompass more services, including APIs, dosage and softgel formulations.
You may also be interested in...
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Deals Of The Week Wonders: Will Pharma Ever Pay More For Companion Diagnostics?
Partnerships between Lilly/Qiagen and BioMarin/Myriad highlight the increasing pace of deals to develop companion diagnostics as the importance of biomarkers and tests to drug development increases. In other deals Clovis buys Eos, Amicus buys Callidus and Versant gives Celgene and Bayer options to acquire drug assets.
Biogen Makes Counterintuitive Move To Tap Exelixis's Scangos As CEO
Shortly after the market closed on June 30, Biogen Idec and Exelixis confirmed leadership changes that will result in Exelixis's long-time CEO George Scangos taking the helm of the Big Biotech July 15